Cormorant Asset Management »

Biohaven shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Biohaven (BHVN) shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Biohaven

Tip: Access up to 7 years of quarterly data

All positions including Biohaven held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Biohaven by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $34M 617k 54.69
2023-12-31 $3.5M 82k 42.80
2023-09-30 $2.1M 82k 26.01
2023-06-30 $2.0M 82k 23.92
2023-03-31 $1.1M 82k 13.66
2022-12-31 $1.1M 82k 13.88

More positions owned by Cormorant Asset Management

Moonlake Immunotherapeutics Class A Ord (MLTX)
Eyepoint Pharmaceuticals Com New (EYPT)
Arcellx Common Stock (ACLX)
Alpine Immune Sciences (ALPN)
Bridgebio Pharma (BBIO)
Praxis Precision Medicines I Com New (PRAX)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Tarsus Pharmaceuticals (TARS)
Longboard Pharmaceuticals In (LBPH)
Edgewise Therapeutics (EWTX)
Crinetics Pharmaceuticals In (CRNX)
Biomea Fusion (BMEA)
Korro Bio (KRRO)
Vaxcyte (PCVX)
Autolus Therapeutics Spon Ads (AUTL)

View all positions for Cormorant Asset Management

Top funds holding Biohaven

Vanguard Group
Stifel Financial
BlackRock
Henderson Group
Suvretta Capital Management
T. Rowe Price Associates
RP Management
Adage Capital Partners GP
Perceptive Advisors
FMR
Geode Capital Management
Darwin Global Management
Citadel Advisors
Holocene Advisors
T. Rowe Price Investment Management

View all funds holding Biohaven